July 13, 2016

Spectrum Pharmaceuticals Settles FOLOTYN® (pralatrexate injection) ANDA Patent Litigation

HENDERSON, Nev.--(BUSINESS WIRE)-- **Spectrum Pharmaceuticals (NasdaqGS: SPPI)**, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that it has settled its ANDA patent litigation relating to FOLOTYN. As a result of the settlement with the last remaining ANDA filer, Fresenius Kabi USA, LLC, and the previously reported settlements with Teva Pharmaceuticals USA, Inc., Dr. Reddy's Laboratories, Ltd. & Dr. Reddy's Laboratories, Inc. and Sandoz Inc., absent certain circumstances, generic versions of FOLOTYN will not be permitted to be marketed in the United States until November 15, 2022. The Company will submit the settlement agreement to the Federal Trade Commission and the Department of Justice. Details of the settlement are confidential.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets six hematology/oncology drugs, and expects an FDA decision on another drug in the second half of 2016. Additionally, Spectrum's pipeline includes three drugs in advanced stages of clinical development that management believes have the potential to transform the Company. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com

Forward-looking statement — This press release contains forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements regarding the anticipated results of the settlements and litigation, statements that relate to Spectrum's business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include whether the court approves the dismissal of the litigation, governmental review of the settlement agreements, potential future challenges from generic companies, the possibility that Spectrum's existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160713005453/en/

Spectrum Pharmaceuticals, Inc.
Shiv Kapoor
Vice President, Strategic Planning & Investor Relations
702-835-6300
InvestorRelations@sppirx.com

Source: Spectrum Pharmaceuticals, Inc.